PFE vs STOK: fair value comparison
Pfizer Inc. and Stoke Therapeutics, Inc. · Updated 2026-10-19
STOK has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PFE currently ranks higher by quality score.
| PFE | STOK | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $28.28 | $24.17 |
| 12-month range | $23.67–$29.58 | $22.37–$38.35 |
| Rank by discount to fair value | #84 of 108 Healthcare | — |
| Rank by quality score | #106 of 301 Healthcare | #107 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | High |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: PFE fair value analysis · STOK fair value analysis